-
Je něco špatně v tomto záznamu ?
Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation
O. Hovorka, V. Subr, D. Větvička, L. Kovář, J. Strohalm, M. Strohalm, A. Benda, M. Hof, K. Ulbrich, B. Ríhová
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
Odkazy
PubMed
20638475
DOI
10.1016/j.ejpb.2010.07.008
Knihovny.cz E-zdroje
- MeSH
- antibiotika antitumorózní metabolismus farmakologie MeSH
- buněčné jádro metabolismus MeSH
- buňky 3T3 MeSH
- DNA metabolismus MeSH
- doxorubicin analogy a deriváty metabolismus farmakologie MeSH
- fluorescenční spektrometrie MeSH
- hydrofobní a hydrofilní interakce MeSH
- lidé MeSH
- lymfom T-buněčný farmakoterapie metabolismus MeSH
- myši MeSH
- nádorové buňky kultivované MeSH
- polymery metabolismus MeSH
- průtoková cytometrie MeSH
- systémy cílené aplikace léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
There is a wide range of techniques utilizing fluorescence of doxorubicin (Dox) commonly used for analysis of intracellular accumulation and destiny of various drug delivery systems containing this anthracycline antibiotic. Unfortunately, results of these studies can be significantly influenced by doxorubicin degradation product, 7,8-dehydro-9,10-desacetyldoxorubicinone (D*) forming spontaneously in aqueous environment, whose fluorescence strongly interfere with that of doxorubicin. Here, we define two microscopy techniques enabling to distinguish and separate Dox and D* emission based either on its spectral properties or on fluorescence lifetime analysis. To analyze influx and nuclear accumulation of Dox (free or polymer-bound) by flow cytometry, we propose using an indirect method based on its DNA intercalation competition with Hoechst 33342 rather than a direct measurement of doxorubicin fluorescence inside the cells.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027395
- 003
- CZ-PrNML
- 005
- 20170621134914.0
- 007
- ta
- 008
- 120816s2010 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejpb.2010.07.008 $2 doi
- 035 __
- $a (PubMed)20638475
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Hovorka, Ondřej, $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. hovorka@biomed.cas.cz $d 1971- $7 xx0062705
- 245 10
- $a Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation / $c O. Hovorka, V. Subr, D. Větvička, L. Kovář, J. Strohalm, M. Strohalm, A. Benda, M. Hof, K. Ulbrich, B. Ríhová
- 520 9_
- $a There is a wide range of techniques utilizing fluorescence of doxorubicin (Dox) commonly used for analysis of intracellular accumulation and destiny of various drug delivery systems containing this anthracycline antibiotic. Unfortunately, results of these studies can be significantly influenced by doxorubicin degradation product, 7,8-dehydro-9,10-desacetyldoxorubicinone (D*) forming spontaneously in aqueous environment, whose fluorescence strongly interfere with that of doxorubicin. Here, we define two microscopy techniques enabling to distinguish and separate Dox and D* emission based either on its spectral properties or on fluorescence lifetime analysis. To analyze influx and nuclear accumulation of Dox (free or polymer-bound) by flow cytometry, we propose using an indirect method based on its DNA intercalation competition with Hoechst 33342 rather than a direct measurement of doxorubicin fluorescence inside the cells.
- 650 _2
- $a buňky 3T3 $7 D016475
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antibiotika antitumorózní $x metabolismus $x farmakologie $7 D000903
- 650 _2
- $a buněčné jádro $x metabolismus $7 D002467
- 650 _2
- $a DNA $x metabolismus $7 D004247
- 650 _2
- $a doxorubicin $x analogy a deriváty $x metabolismus $x farmakologie $7 D004317
- 650 _2
- $a systémy cílené aplikace léků $7 D016503
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a lymfom T-buněčný $x farmakoterapie $x metabolismus $7 D016399
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a polymery $x metabolismus $7 D011108
- 650 _2
- $a fluorescenční spektrometrie $7 D013050
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Šubr, Vladimír, $d 1957- $7 xx0088449 $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Větvička, David $7 xx0214483 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Kovář, Lubomír $7 xx0126758 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Strohalm, Jiří $7 xx0109134 $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Strohalm, Martin $7 xx0143548 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Benda, Aleš $7 xx0228989 $u J. Heyrovsky Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Hof, Martin, $d 1962- $7 ntka172581 $u J. Heyrovsky Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Ulbrich, Karel, $d 1947- $7 jo2004259877 $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Říhová, Blanka, $d 1942- $7 jo20000073671 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 773 0_
- $w MED00001640 $t European journal of pharmaceutics and biopharmaceutics official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V $x 1873-3441 $g Roč. 76, č. 3 (2010), s. 514-524
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20638475 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20170621135333 $b ABA008
- 999 __
- $a ok $b bmc $g 949437 $s 784741
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 76 $c 3 $d 514-524 $e 20100716 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
- LZP __
- $b NLK112 $a Pubmed-20120816/11/02